Multicenter, single-arm, phase II study of the tri functional antibody catumaxomab (anti EpCAM x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer

Update Il y a 5 ans
Reference: EUCTR2006-004484-54

Woman Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Determination of the safety of an adjuvant treatment with catumaxomab in patients with epithelial ovarian cancer in terms of post-operative complication rate.


Inclusion criteria

  • Epithelial Ovarian Cancer